View Financial HealthBiomark Diagnostics 배당 및 자사주 매입배당 기준 점검 0/6Biomark Diagnostics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-5.1%자사주 매입 수익률총 주주 수익률-5.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 16Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in OncologyBioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.공시 • Jan 01Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics.공시 • Oct 14Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025.공시 • May 12Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular SciencesBioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.공시 • Mar 31Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in fundingOn March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed.공시 • Mar 27Biomark Diagnostics Inc. announced a financing transactionBiomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000.공시 • Oct 21Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024. Location: british columbia, richmond Canada공시 • Sep 10Biomark Diagnostics Completes Testing of over 5,400 Subjects as Part of A Validation Study for Early Lung Cancer DetectionBioMark Diagnostics Inc. announced the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes. BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease.Reported Earnings • Aug 30First quarter 2025 earnings released: CA$0.007 loss per share (vs CA$0.005 loss in 1Q 2024)First quarter 2025 results: CA$0.007 loss per share (further deteriorated from CA$0.005 loss in 1Q 2024). Revenue: CA$38.3k (down 3.6% from 1Q 2024). Net loss: CA$623.3k (loss widened 49% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.Reported Earnings • Jul 28Full year 2024 earnings released: CA$0.017 loss per share (vs CA$0.022 loss in FY 2023)Full year 2024 results: CA$0.017 loss per share (improved from CA$0.022 loss in FY 2023). Revenue: CA$163.2k (up 6.3% from FY 2023). Net loss: CA$1.43m (loss narrowed 23% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Reported Earnings • Mar 03Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (in line with 3Q 2023). Revenue: CA$41.5k (up 13% from 3Q 2023). Net loss: CA$406.8k (loss widened 3.3% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 17% per year.Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Member of Advisory Board AI Berkeley was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Jan 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$118k). Minor Risks Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Market cap is less than US$100m (€15.1m market cap, or US$16.4m).New Risk • Jan 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$119k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€13.6m market cap, or US$14.9m).공시 • Dec 29Biomark Diagnostics Inc. announced that it has received CAD 1.9 million in fundingBiomark Diagnostics Inc announced that it has completed a non-brokered private placement of 7,600,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 1,900,000 on December 29, 2023. The securities issued under the private placement will be subject to a hold period of four months and one day. Each unit consists of one common share and one-full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.45 per share for a period of three years from the closing date of the private placement, subject to an acceleration clause. Certain Insiders, Directors and Officers subscribed for a portion of this placement. No Finders' fees were payable on the private placement.Reported Earnings • Nov 29Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.006 loss in 2Q 2023). Revenue: CA$42.1k (up 2.9% from 2Q 2023). Net loss: CA$210.5k (loss narrowed 60% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.공시 • Oct 13Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023.Reported Earnings • Aug 30First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: CA$39.7k (up 11% from 1Q 2023). Net loss: CA$418.9k (flat on 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.New Risk • Aug 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.75m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$920k free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-CA$1.1m). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (CA$153k revenue, or US$115k). Market cap is less than US$10m (€8.75m market cap, or US$9.65m).Reported Earnings • Aug 01Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.02 loss in FY 2022)Full year 2023 results: CA$0.022 loss per share (further deteriorated from CA$0.02 loss in FY 2022). Revenue: CA$153.5k (up 249% from FY 2022). Net loss: CA$1.84m (loss widened 27% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.공시 • Jan 12BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial LaunchBioMark Diagnostics Inc. announced several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce that enrollment for its pivotal lung cancer screening study exceeded 1,000 participants in less than one year. The lung cancer screening demonstration project led by Dr. Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec- Université Laval - IUCPQ-UL), is intended to combine BioMark's metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk Quebecers get access to an accurate and accessible lung cancer screening program. The multimodal study was designed to recruit 4,000 participants from eight major hospitals across in Quebec, generating data that can support BioMark's implementation within the Province of Quebec. The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study. BioMark's blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe's screen-eligible population who are most likely to benefit from a CT scan. The study is being conducted by Pr Sébastien Couraud, pulmonologist at the Hospices Civils de Lyon (HCL) and through a partnership with France- based TransDiag. Through the ILYAD study, the investigators are studying the participation rate during the initial round in the lung cancer screening program and assessing the performance of several blood- based biomarkers for the detection of cancers in screened individuals. The test being developed by the consortium would offer the opportunity to screen nearly 4 million individuals in France who are eligible for lung cancer screening under current European guidelines. These at-risk individuals are aged between 50 and 75 and have a history of heavy smoking. The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies. The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification.Is New 90 Day High Low • Mar 03New 90-day high: €0.21The company is up 141% from its price of €0.088 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 20B 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 20B 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Biomark Diagnostics 배당 수익률 vs 시장20B의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (20B)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.2%분석가 예측 (20B) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 20B 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 20B 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 20B 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 20B 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 14:25종가2026/05/22 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biomark Diagnostics Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 16Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in OncologyBioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.
공시 • Jan 01Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics.
공시 • Oct 14Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025.
공시 • May 12Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular SciencesBioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.
공시 • Mar 31Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in fundingOn March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed.
공시 • Mar 27Biomark Diagnostics Inc. announced a financing transactionBiomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000.
공시 • Oct 21Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024. Location: british columbia, richmond Canada
공시 • Sep 10Biomark Diagnostics Completes Testing of over 5,400 Subjects as Part of A Validation Study for Early Lung Cancer DetectionBioMark Diagnostics Inc. announced the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes. BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease.
Reported Earnings • Aug 30First quarter 2025 earnings released: CA$0.007 loss per share (vs CA$0.005 loss in 1Q 2024)First quarter 2025 results: CA$0.007 loss per share (further deteriorated from CA$0.005 loss in 1Q 2024). Revenue: CA$38.3k (down 3.6% from 1Q 2024). Net loss: CA$623.3k (loss widened 49% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.
Reported Earnings • Jul 28Full year 2024 earnings released: CA$0.017 loss per share (vs CA$0.022 loss in FY 2023)Full year 2024 results: CA$0.017 loss per share (improved from CA$0.022 loss in FY 2023). Revenue: CA$163.2k (up 6.3% from FY 2023). Net loss: CA$1.43m (loss narrowed 23% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 03Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (in line with 3Q 2023). Revenue: CA$41.5k (up 13% from 3Q 2023). Net loss: CA$406.8k (loss widened 3.3% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 17% per year.
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Member of Advisory Board AI Berkeley was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Jan 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$118k). Minor Risks Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Market cap is less than US$100m (€15.1m market cap, or US$16.4m).
New Risk • Jan 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$119k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€13.6m market cap, or US$14.9m).
공시 • Dec 29Biomark Diagnostics Inc. announced that it has received CAD 1.9 million in fundingBiomark Diagnostics Inc announced that it has completed a non-brokered private placement of 7,600,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 1,900,000 on December 29, 2023. The securities issued under the private placement will be subject to a hold period of four months and one day. Each unit consists of one common share and one-full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.45 per share for a period of three years from the closing date of the private placement, subject to an acceleration clause. Certain Insiders, Directors and Officers subscribed for a portion of this placement. No Finders' fees were payable on the private placement.
Reported Earnings • Nov 29Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.006 loss in 2Q 2023). Revenue: CA$42.1k (up 2.9% from 2Q 2023). Net loss: CA$210.5k (loss narrowed 60% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.
공시 • Oct 13Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023.
Reported Earnings • Aug 30First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: CA$39.7k (up 11% from 1Q 2023). Net loss: CA$418.9k (flat on 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
New Risk • Aug 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.75m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$920k free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-CA$1.1m). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (CA$153k revenue, or US$115k). Market cap is less than US$10m (€8.75m market cap, or US$9.65m).
Reported Earnings • Aug 01Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.02 loss in FY 2022)Full year 2023 results: CA$0.022 loss per share (further deteriorated from CA$0.02 loss in FY 2022). Revenue: CA$153.5k (up 249% from FY 2022). Net loss: CA$1.84m (loss widened 27% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
공시 • Jan 12BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial LaunchBioMark Diagnostics Inc. announced several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce that enrollment for its pivotal lung cancer screening study exceeded 1,000 participants in less than one year. The lung cancer screening demonstration project led by Dr. Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec- Université Laval - IUCPQ-UL), is intended to combine BioMark's metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk Quebecers get access to an accurate and accessible lung cancer screening program. The multimodal study was designed to recruit 4,000 participants from eight major hospitals across in Quebec, generating data that can support BioMark's implementation within the Province of Quebec. The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study. BioMark's blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe's screen-eligible population who are most likely to benefit from a CT scan. The study is being conducted by Pr Sébastien Couraud, pulmonologist at the Hospices Civils de Lyon (HCL) and through a partnership with France- based TransDiag. Through the ILYAD study, the investigators are studying the participation rate during the initial round in the lung cancer screening program and assessing the performance of several blood- based biomarkers for the detection of cancers in screened individuals. The test being developed by the consortium would offer the opportunity to screen nearly 4 million individuals in France who are eligible for lung cancer screening under current European guidelines. These at-risk individuals are aged between 50 and 75 and have a history of heavy smoking. The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies. The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification.
Is New 90 Day High Low • Mar 03New 90-day high: €0.21The company is up 141% from its price of €0.088 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.